Literature DB >> 1467165

Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation.

I C Robieux1, J D Kellner, M J Coppes, D Shaw, E Brown, C Good, H O'Brodovich, D Manson, N F Olivieri, A Zipursky.   

Abstract

The objectives of the study were to compare the efficacy and safety of a continuous infusion (CIV) of morphine and intermittent parenteral opioids (IPO) in children with sickle cell vaso-occlusive crises (VOCs); to determine whether 50% oxygen administration through a face mask can reduce the duration of severe pain in patients receiving CIV morphine; and to measure morphine concentration at steady state for pharmacokinetic and pharmacodynamic analysis in patients receiving CIV morphine. The study was designed as a prospective, controlled, "before-and-after" evaluation of two different analgesic regimens. For patients receiving CIV morphine, there was a randomized, double-blind, placebo-controlled study of O2 vs. air. The patients were 66 children with sickle cell disease, 3-18 years old, requiring opioid therapy for severe VOC (32 patients in phase A, 34 in phase B). The analgesic regimens were as follows: phase A: meperidine, morphine, or codeine IM or IV bolus every 3 or 4 hours; phase B: morphine sulfate, loading dose 0.15 mg followed by CIV 0.04 mg/kg/hr. The infusion rate was adjusted every 8 hours according to pain and/or symptoms of opioid toxicity. Pain assessment was by behavioral observation (BPS). In terms of results, the mean opioid dose (morphine equivalent) was similar in both groups (0.032 +/- 0.020 mg/kg/hr in phase A and 0.035 +/- 0.011 in phase B). However, the duration of severe pain was significantly shorter in phase B (0.9 +/- 1.0 days) than in phase A (2.0 +/- 1.8 days). No severe opioid toxicity was observed in either group. Oxygen did not shorten the duration of severe pain compared to the placebo group (0.94 +/- 1.08 and 0.95 +/- 1.19 days, respectively) nor did it prevent the appearance of new pain sites. Pharmacokinetic analysis was performed in 24 patients of phase B. Total body clearance (TBC) of morphine was greater in children before puberty than after (40.4 +/- 10 vs. 28 +/- 11 mL/kg/min; p < 0.05). In conclusion, in children with severe VOCs, continuous infusion of morphine provides better analgesia than intermittent opioid therapy. Fifty percent oxygen inhalation had no effect on the duration of pain.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1467165     DOI: 10.3109/08880019209016603

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  10 in total

1.  Morphine and morphine-6-glucuronide in the plasma and cerebrospinal fluid of children.

Authors:  R D Hain; A Hardcastle; C R Pinkerton; G W Aherne
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

Review 2.  Sickle cell disease.

Authors:  Martin M Meremikwu; Uduak Okomo
Journal:  BMJ Clin Evid       Date:  2011-02-14

Review 3.  Prediction of morphine clearance in the paediatric population : how accurate are the available pharmacokinetic models?

Authors:  Elke H J Krekels; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-11       Impact factor: 6.447

Review 4.  Pain management in children with sickle cell disease.

Authors:  Jennifer Stinson; Basem Naser
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 5.  Sickle cell disease.

Authors:  Martin M Meremikwu
Journal:  BMJ Clin Evid       Date:  2009-03-27

Review 6.  Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence.

Authors:  Mj Kennedy
Journal:  Clin Pharmacol Ther       Date:  2008-10-29       Impact factor: 6.875

Review 7.  Inter-individual variation in morphine clearance in children.

Authors:  Mohammed I Altamimi; Imti Choonara; Helen Sammons
Journal:  Eur J Clin Pharmacol       Date:  2015-04-08       Impact factor: 2.953

8.  Prevention of Morbidity in sickle cell disease--qualitative outcomes, pain and quality of life in a randomised cross-over pilot trial of overnight supplementary oxygen and auto-adjusting continuous positive airways pressure (POMS2a): study protocol for a randomised controlled trial.

Authors:  Jo Howard; Baba Inusa; Christina Liossi; Eufemia Jacob; Patrick B Murphy; Nicholas Hart; Johanna Gavlak; Sati Sahota; Maria Chorozoglou; Carol Nwosu; Maureen Gwam; Atul Gupta; David C Rees; Swee Lay Thein; Isabel C Reading; Fenella J Kirkham; Man Yeung Edith Cheng
Journal:  Trials       Date:  2015-08-25       Impact factor: 2.279

9.  Sickle cell disease: management options and challenges in developing countries.

Authors:  Daniel Ansong; Alex Osei Akoto; Delaena Ocloo; Kwaku Ohene-Frempong
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-11-04       Impact factor: 2.576

10.  Guidelines on neonatal screening and painful vaso-occlusive crisis in sickle cell disease: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: Project guidelines: Associação Médica Brasileira - 2016.

Authors:  Josefina Aparecida Pellegrini Braga; Mônica Pinheiro de Almeida Veríssimo; Sara Teresinha Olalla Saad; Rodolfo Delfini Cançado; Sandra Regina Loggetto
Journal:  Rev Bras Hematol Hemoter       Date:  2016-04-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.